Developing an entry strategy for the "regenerative medicine" market.
- GOOD HEALTH AND
WELL-BEING - INDUSTRY, INNOVATION AND
INFRASTRUCTURE
Issue
Opportunity loss in "cell culture," a critical process in regenerative medicine
Regenerative medicine is highly anticipated as a treatment capable of curing diseases previously deemed untreatable. However, the “cell culture” process, essential for producing regenerative medicine drugs, requires substantial capital investment, advanced technology, and manual labor, raising concerns about human error and the need for skilled technician training.
Approach
Proposals to Japanese companies with advanced expertise and technologies cultivated in semiconductor manufacturing.
For the mass production of regenerative medicine drugs, the introduction of “automated cell culture systems” is considered particularly promising. Given that manufacturing processes for regenerative medicine drugs are difficult to modify once established, an early market entry strategy to secure a first-mover advantage is deemed advantageous.
By applying the knowledge gained from NC Medical Research’s cell therapy drug development, e-solutions proposed that Japanese companies with advanced semiconductor manufacturing capabilities consider entering the “contract cell culture” market and producing “automated cell culture systems.”